新鄉化纖(000949.SZ):擬出資5000萬元設菌草公司
格隆匯2月22日丨新鄉化纖(000949.SZ)公佈,為推動公司在生物質菌草新材料方面的業務發展,公司擬出資5000萬元設立全資子公司新鄉菌草新材料技術有限公司(暫定名,“菌草公司”)。
目前我國再生纖維素纖維原料(木漿)對國外進口的依賴度較高,極大限制了我國再生纖維素纖維行業的發展。菌草技術是“以草代木”發展起來的中國特有技術,能夠實現光、熱、水三大農業資源綜合高效利用。
公司利用菌草技術製漿能力優勢,將其應用於生物質纖維素長絲行業,將為公司提供優質非木質原料,有利於公司進一步降本增效,是公司增強產業供應鏈安全性的重要一步,也是菌草技術在紡織領域大規模產業化應用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.